Received: 20 May 2020
Accepted: 26 July 2020
First Online: 8 August 2020
Ethics approval and consent to participate
: The local ethics committee of Hospital University of Strasbourg approved the study (reference CE: 2020-35).
: According to the advice of ethics committee and in light of the clinical and epidemiological context, oral consent for the use of medical data could not be obtained for all patients, but was confirmed systematically by a relative and after the critical stage by the patient itself or its relative in case of death.
: Dr. Anheim reports personal fees from Johnson and Johnson, personal fees from Actelion Pharmaceuticals, personal fees from Teva, personal fees from UCB, from AbbVie, personal fees from Aguettan, and personal fees from LVL, outside the submitted work. The other authors have no conflicts of interest to declare.